A statistical method for estimating the no-observed-adverse-event-level

2021/01/02 by Hothorn, Ludwig A.
#Applications (stat.AP) #FOS: Computer and information sciences

paper · doi:10.48550/arxiv.2101.00427

Abstract

In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

Related

• Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances
• Semi-parametric Benchmark Dose Analysis with Monotone Additive Models
• An evaluation framework for new approach methodologies (NAMs) for human health safety assessment
• New approach methodologies in human regulatory toxicology – Not if, but how and when!
• Quantitative weight of evidence to assess confidence in potential modes of action